Two Sigma Advisers
OCUL icon

Two Sigma Advisers’s Ocular Therapeutix OCUL Stock Holding History

Two Sigma Advisers’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-142,924
Closed -$1.74M – 1473
2025
Q4 		$1.74M Buy
142,924
+29,024
+25% +$353K ﹤0.01% 1242
2025
Q3 		$1.33M Buy
+113,900
New +$1.36M ﹤0.01% 1322
2025
Q2 		– Sell
-73,100
Closed -$536K – 2469
2025
Q1 		$536K Buy
73,100
+36,400
+99% +$280K ﹤0.01% 1745
2024
Q4 		$313K Buy
36,700
+26,300
+253% +$257K ﹤0.01% 1962
2024
Q3 		$90.5K Sell
10,400
-26,900
-72% -$222K ﹤0.01% 2176
2024
Q2 		$255K Buy
+37,300
New +$230K ﹤0.01% 2134
2023
Q4 		– Sell
-33,700
Closed -$106K – 2603
2023
Q3 		$106K Sell
33,700
-320,500
-90% -$1.31M ﹤0.01% 2202
2023
Q2 		$1.83M Buy
354,200
+44,800
+14% +$266K ﹤0.01% 1253
2023
Q1 		$1.63M Sell
309,400
-12,300
-4% -$58.4K ﹤0.01% 1379
2022
Q4 		$904K Sell
321,700
-34,500
-10% -$114K ﹤0.01% 1618
2022
Q3 		$1.48M Sell
356,200
-32,900
-8% -$166K ﹤0.01% 1333
2022
Q2 		$1.56M Sell
389,100
-296,000
-43% -$1.12M ﹤0.01% 1344
2022
Q1 		$3.39M Sell
685,100
-105,700
-13% -$586K 0.01% 982
2021
Q4 		$5.51M Sell
790,800
-285,500
-27% -$2.22M 0.01% 726
2021
Q3 		$10.8M Sell
1,076,300
-110,800
-9% -$1.24M 0.03% 491
2021
Q2 		$16.8M Sell
1,187,100
-35,200
-3% -$535K 0.04% 380
2021
Q1 		$20.1M Buy
1,222,300
+157,200
+15% +$3.03M 0.06% 361
2020
Q4 		$22M Buy
1,065,100
+740,100
+228% +$11M 0.06% 326
2020
Q3 		$2.47M Buy
325,000
+291,100
+859% +$2.42M 0.01% 1055
2020
Q2 		$282K Buy
+33,900
New +$225K ﹤0.01% 2142

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Advisers's OCUL Position: Q1 2026 in Review

Two Sigma Advisers sold out of Ocular Therapeutix (OCUL) in Q1 2026, closing a stake of 142,924 shares — an estimated $1.74M sold.

Two Sigma Advisers first reported a position in OCUL in Q2 2020 and held it in 20 quarters. The position peaked at $22M in Q4 2020. 270 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Two Sigma Advisers reported no remaining Ocular Therapeutix position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 142,924 Ocular Therapeutix shares in Q1 2026, an estimated $1.74M.
  • Two Sigma Advisers first reported a position in Ocular Therapeutix in Q2 2020 and held it in 20 quarters.
  • Two Sigma Advisers's Ocular Therapeutix position peaked at $22M in Q4 2020.
  • 270 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.